GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » Tax Expense

Adcock Ingram Holdings (JSE:AIP) Tax Expense : R301 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings Tax Expense?

Adcock Ingram Holdings's tax expense for the months ended in Dec. 2023 was R161 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was R301 Mil.


Adcock Ingram Holdings Tax Expense Historical Data

The historical data trend for Adcock Ingram Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adcock Ingram Holdings Tax Expense Chart

Adcock Ingram Holdings Annual Data
Trend Sep13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 269.44 247.82 243.76 301.27 307.22

Adcock Ingram Holdings Semi-Annual Data
Mar14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.12 149.15 167.18 140.05 161.33

Adcock Ingram Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R301 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adcock Ingram Holdings  (JSE:AIP) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Adcock Ingram Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Adcock Ingram Holdings (JSE:AIP) Business Description

Traded in Other Exchanges
N/A
Address
1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.

Adcock Ingram Holdings (JSE:AIP) Headlines